Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAMOQUIN HYDROCHLORIDE vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Treatment of acute malaria caused by chloroquine-sensitive or chloroquine-resistant Plasmodium falciparum and other Plasmodium species,Treatment of uncomplicated malaria (FDA-approved),Off-label: intermittent preventive treatment of malaria in pregnancy (IPTp) in combination with sulfadoxine-pyrimethamine
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Terminal elimination half-life ranges 9–21 days (mean ~14 days) due to extensive tissue binding; clinical context: steady-state achieved after 4–6 weeks, prolonged half-life allows weekly dosing for malaria prophylaxis.
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Primarily metabolized in the liver by CYP2C8 to the active metabolite desethylamodiaquine. Also undergoes N-oxidation and conjugation.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Primarily hepatic metabolism (approx. 60-70%) with metabolites excreted in bile and feces; renal excretion of unchanged drug accounts for <5% of the dose. Fecal elimination accounts for ~20-30% of the dose, with minor biliary contribution.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
Approximately 90% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
50-60%, primarily to albumin and α1-acid glycoprotein.
Mean Vd ~100–300 L/kg (extremely large due to extensive tissue sequestration, especially in erythrocytes and liver); indicates deep tissue distribution.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Oral bioavailability is approximately 75–85% (first-pass metabolism limited).
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) due to risk of toxicity.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
5 mg base/kg (8.3 mg salt/kg) orally once weekly for prophylaxis; 10 mg base/kg (16.6 mg salt/kg) initially, followed by 5 mg base/kg at 6, 24, and 48 hours for treatment.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
Use with caution; consider lower initial doses and monitor for QT prolongation and neuropsychiatric effects due to age-related changes in clearance.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
Amodiaquine hydrochloride is associated with hepatotoxicity and agranulocytosis. Use is contraindicated in patients with previous adverse reactions to amodiaquine. Prolonged use for prophylaxis is not recommended due to risk of severe hepatic injury and blood dyscrasias.
No FDA black box warning.
Monitor liver function tests; discontinue if signs of hepatotoxicity (elevated transaminases, jaundice). Risk of agranulocytosis, neutropenia; monitor CBC. Caution in patients with G6PD deficiency (risk of hemolysis). Can cause QT prolongation; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Reduce dose in severe hepatic impairment. Use in pregnancy only if potential benefit outweighs risk (no adequate studies).
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hypersensitivity to amodiaquine or other 4-aminoquinolines (e.g., chloroquine); history of hepatic disease or blood dyscrasias (e.g., agranulocytosis, neutropenia) associated with amodiaquine; concomitant use with hepatotoxic drugs or drugs known to cause agranulocytosis; patients with known G6PD deficiency (relative, use with caution).
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
No specific food restrictions; however, administration with fatty meals may enhance absorption. Avoid grapefruit juice due to potential CYP2C8 inhibition. Maintain adequate hydration and caloric intake.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Generally considered safe for malaria treatment; no evidence of increased malformations. Overall risk category C: Risk cannot be ruled out.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Excreted in breast milk in small amounts. M/P ratio not established. Use with caution, especially in infants with G6PD deficiency. The WHO considers amodiaquine compatible with breastfeeding during malaria treatment.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No specific dose adjustment required in pregnancy; standard dosing recommended for malaria treatment (based on weight). Pharmacokinetic changes in pregnancy (increased volume of distribution) do not necessitate dose modification.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Camoquin hydrochloride (amodiaquine) is an antimalarial agent related to chloroquine. It is active against erythrocytic stages of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. Not effective against exo-erythrocytic forms. Hepatic metabolism via CYP2C8; genetic variants may affect toxicity. Monitor for hepatotoxicity and agranulocytosis, especially with prolonged use. Contraindicated in patients with liver disease or history of psychosis. Use with caution in G6PD deficiency due to risk of hemolysis.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take exactly as prescribed; do not stop early even if feeling better.,May cause nausea; taking with food or milk can help reduce stomach upset.,Avoid alcohol while on this medication due to increased risk of hepatotoxicity.,Report any yellowing of skin or eyes, dark urine, severe fatigue, or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not take with fever or other antimalarials unless directed by your physician.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAMOQUIN HYDROCHLORIDE vs ARALEN HYDROCHLORIDE, answered by our medical review team.
CAMOQUIN HYDROCHLORIDE is a Antimalarial that works by Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAMOQUIN HYDROCHLORIDE and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAMOQUIN HYDROCHLORIDE is: 600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAMOQUIN HYDROCHLORIDE and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAMOQUIN HYDROCHLORIDE is classified as Category C. First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester:. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.